| Exploring the Etiological Links behind Neurodegenerative Diseases: Inflammatory Cytokines and Bioactive Kynurenines M Tanaka, J Toldi, L Vécsei International Journal of Molecular Sciences, 2020 | 179 | 2020 |
| Immune Influencers in Action: Metabolites and Enzymes of the Tryptophan-Kynurenine Metabolic Pathway M Tanaka, F Tóth, H Polyák, Á Szabó, Y Mándi, L Vécsei Biomedicines 2021 (9), 734, 2021 | 168 | 2021 |
| Inhibition of multidrug resistance of cancer cells by natural diterpenes, triterpenes and carotenoids J Molnár, N Gyémánt, M Tanaka, J Hohmann, E Bergmann-Leitner, ... Current pharmaceutical design 12 (3), 287-311, 2006 | 143 | 2006 |
| Mitochondrial Impairment: A Common Motif in Neuropsychiatric Presentation? The Link to the Tryptophan–Kynurenine Metabolic System M Tanaka, S Ágnes, S Eleonóra, P Helga, T Fanni, V László Cells 11 (16), 2607, 2022 | 122 | 2022 |
| Searching for Peripheral Biomarkers in Neurodegenerative Diseases: The Tryptophan-Kynurenine Metabolic Pathway N Török, M Tanaka, L Vécsei International Journal of Molecular Sciences 2020 (21), 9338, 2020 | 99 | 2020 |
| Neurogenic Inflammation: The Participant in Migraine and Recent Advancements in Translational Research E Spekker, M Tanaka, Á Szabó, L Vécsei Biomedicines 10, 76, 2021 | 81 | 2021 |
| Are Kynurenines Accomplices or Principal Villains in Dementia? Maintenance of Kynurenine Metabolism M Tanaka, Z Bohar, L Vecsei Molecules, 2020 | 80 | 2020 |
| In vitro search for synergy between flavonoids and epirubicin on multidrug-resistant cancer cells N Gyémánt, M Tanaka, S Antus, J Hohmann, O Csuka, L Mándoky, ... In vivo 19 (2), 367-374, 2005 | 80 | 2005 |
| Modelling the neurodevelopmental pathogenesis in neuropsychiatric disorders. Bioactive kynurenines and their analogues as neuroprotective agents—in celebration of 80th … M Tanaka, E Spekker, Á Szabó, H Polyák, L Vécsei Journal of Neural Transmission, 2022 | 72 | 2022 |
| Editorial of special issue “crosstalk between depression, anxiety, and dementia: comorbidity in behavioral neurology and neuropsychiatry” M Tanaka, L Vécsei Biomedicines 9 (5), 517, 2021 | 72 | 2021 |
| Memory Enhancement with Kynurenic Acid and Its Mechanisms in Neurotransmission D Martos, B Tuka, M Tanaka, L Vécsei, G Telegdy Biomedicines 2022 (10), 849, 2022 | 70 | 2022 |
| Monitoring the redox status in multiple sclerosis M Tanaka, L Vécsei Biomedicines 8 (10), 406, 2020 | 68 | 2020 |
| Neurotransmissions of antidepressant-like effects of kisspeptin-13 M Tanaka, K Csabafi, G Telegdy Regulatory peptides 180, 1-4, 2013 | 65 | 2013 |
| Antidepressant-like effects of kynurenic acid in a modified forced swim test M Tanaka, Z Bohar, D Martos, G Telegdy, L Vecsei Pharmacological Reports, 2020 | 60 | 2020 |
| Co-Players in Chronic Pain: Neuroinflammation and the Tryptophan-Kynurenine Metabolic Pathway M Tanaka, N Török, F Tóth, Á Szabó, V L. Biomedicines 9, 897, 2021 | 58* | 2021 |
| Monitoring the kynurenine system: Concentrations, ratios or what else? M Tanaka, L Vécsei Advances in Clinical and Experimental Medicine 30 (8), 2021 | 57 | 2021 |
| Editorial of Special Issue ‘Dissecting Neurological and Neuropsychiatric Diseases: Neurodegeneration and Neuroprotection’ M Tanaka, L Vécsei International Journal of Molecular Sciences 2022 (23), 6991, 2022 | 56 | 2022 |
| Antidepressant-like effects of the CRF family peptides, urocortin 1, urocortin 2 and urocortin 3 in a modified forced swimming test in mice M Tanaka, G Telegdy Brain research bulletin 75 (5), 509-512, 2008 | 56 | 2008 |
| Crosstalk between existential phenomenological psychotherapy and neurological sciences in mood and anxiety disorders L Balogh, M Tanaka, N Török, L Vécsei, S Taguchi Biomedicines 9 (4), 340, 2021 | 55 | 2021 |
| Reversal of multidrug resistance of cancer cells in vitro: Modification of drug resistance by selected carotenoids N Gyemant, M Tanaka, P Molnar, J Deli, L Mandoky, J Molnar Anticancer Research, 2006 | 49 | 2006 |
László Vécsei MD PhD DScUniversity of Szeged, Faculty of Medicine, Department of NeurologyVerified email at med.u-szeged.hu
